Literature DB >> 26190444

Pseudomonas aeruginosa nosocomial pneumonia: impact of pneumonia classification.

Scott T Micek1, Marin H Kollef2, Antoni Torres3, Catherine Chen2, Jordi Rello4, Jean Chastre5, Massimo Antonelli6, Tobias Welte7, Bernard Clair8, Helmut Ostermann9, Esther Calbo10, Richard Wunderink11, Francesco Menichetti12, Garrett Schramm13, Vandana Menon14.   

Abstract

OBJECTIVE: To describe and compare the mortality associated with nosocomial pneumonia due to Pseudomonas aeruginosa (Pa-NP) according to pneumonia classification (community-onset pneumonia [COP], hospital-acquired pneumonia [(HAP], and ventilator-associated pneumonia [VAP]).
DESIGN: We conducted a retrospective cohort study of adults with Pa-NP. We compared mortality for Pa-NP among patients with COP, HAP, and VAP and used logistic regression to identify risk factors for hospital mortality and inappropriate initial antibiotic therapy (IIAT).
SETTING: Twelve acute care hospitals in 5 countries (United States, 3; France, 2; Germany, 2; Italy, 2; and Spain, 3). PATIENTS/PARTICIPANTS: A total of 742 patients with Pa-NP.
RESULTS: Hospital mortality was greater for those with VAP (41.9%) and HAP (40.1%) compared with COP (24.5%) (P<.001). In multivariate analyses, independent predictors of hospital mortality differed by pneumonia classification (COP: need for mechanical ventilation and intensive care; HAP: multidrug-resistant isolate; VAP: IIAT, increasing age, increasing Charlson comorbidity score, bacteremia, and use of vasopressors). Presence of multidrug resistance was identified as an independent predictor of IIAT for patients with COP and HAP, whereas recent antibiotic administration was protective in patients with VAP.
CONCLUSIONS: Among patients with Pa-NP, pneumonia classification identified patients with different risks for hospital mortality. Specific risk factors for hospital mortality also differed by pneumonia classification and multidrug resistance appeared to be an important risk factor for IIAT. These findings suggest that pneumonia classification for P. aeruginosa identifies patients with different mortality risks and specific risk factors for outcome and IIAT.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26190444     DOI: 10.1017/ice.2015.167

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  19 in total

1.  Influence of Excipients on the Antimicrobial Activity of Tobramycin Against Pseudomonas aeruginosa Biofilms.

Authors:  Tania Bahamondez-Canas; Hugh D C Smyth
Journal:  Pharm Res       Date:  2018-01-02       Impact factor: 4.200

Review 2.  Two-stage approach to total knee arthroplasty using colistin-loaded articulating cement spacer for vancomycin-resistant Pseudomonas aeruginosa infection in an arthritic knee.

Authors:  Moon Jong Chang; Min Kyu Song; Jae Hoon Shin; Chan Yoon; Chong Bum Chang; Seung-Baik Kang
Journal:  Eur J Orthop Surg Traumatol       Date:  2018-06-18

3.  Ablation of PDE4B protects from Pseudomonas aeruginosa-induced acute lung injury in mice by ameliorating the cytostorm and associated hypothermia.

Authors:  Lina Abou Saleh; Abigail Boyd; Ileana V Aragon; Anna Koloteva; Domenico Spadafora; Wadad Mneimneh; Robert A Barrington; Wito Richter
Journal:  FASEB J       Date:  2021-09       Impact factor: 5.834

4.  Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.

Authors:  Ghady Haidar; Nathan J Philips; Ryan K Shields; Daniel Snyder; Shaoji Cheng; Brian A Potoski; Yohei Doi; Binghua Hao; Ellen G Press; Vaughn S Cooper; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2017-07-01       Impact factor: 9.079

5.  Vancomycin-Resistant Pseudomonas Aeroginosa in the Cases of Trauma.

Authors:  Koorosh Ahmadi; Amir Masoud Hashemian; Ehsan Bolvardi; Peyman Khadem Hosseini
Journal:  Med Arch       Date:  2016-01-31

6.  A cohort study of bacteremic pneumonia: The importance of antibiotic resistance and appropriate initial therapy?

Authors:  Cristina Vazquez Guillamet; Rodrigo Vazquez; Jonas Noe; Scott T Micek; Marin H Kollef
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 7.  Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns.

Authors:  Catia Cilloniz; Ignacio Martin-Loeches; Carolina Garcia-Vidal; Alicia San Jose; Antoni Torres
Journal:  Int J Mol Sci       Date:  2016-12-16       Impact factor: 5.923

Review 8.  Recent advances in understanding Pseudomonas aeruginosa as a pathogen.

Authors:  Jens Klockgether; Burkhard Tümmler
Journal:  F1000Res       Date:  2017-07-28

9.  Estimating the burden of antimicrobial resistance: a systematic literature review.

Authors:  Nichola R Naylor; Rifat Atun; Nina Zhu; Kavian Kulasabanathan; Sachin Silva; Anuja Chatterjee; Gwenan M Knight; Julie V Robotham
Journal:  Antimicrob Resist Infect Control       Date:  2018-04-25       Impact factor: 4.887

10.  Intensive care unit patients with lower respiratory tract nosocomial infections: the ENIRRIs project.

Authors:  Gennaro De Pascale; Otavio T Ranzani; Saad Nseir; Jean Chastre; Tobias Welte; Massimo Antonelli; Paolo Navalesi; Eugenio Garofalo; Andrea Bruni; Luis Miguel Coelho; Szymon Skoczynski; Federico Longhini; Fabio Silvio Taccone; David Grimaldi; Helmut J F Salzer; Christoph Lange; Filipe Froes; Antoni Artigas; Emili Díaz; Jordi Vallés; Alejandro Rodríguez; Mauro Panigada; Vittoria Comellini; Luca Fasano; Paolo M Soave; Giorgia Spinazzola; Charles-Edouard Luyt; Francisco Alvarez-Lerma; Judith Marin; Joan Ramon Masclans; Davide Chiumello; Angelo Pezzi; Marcus Schultz; Hafiz Mohamed; Menno Van Der Eerden; Roger A S Hoek; D A M P J Gommers; Marta Di Pasquale; Rok Civljak; Marko Kutleša; Matteo Bassetti; George Dimopoulos; Stefano Nava; Fernando Rios; Fernando G Zampieri; Pedro Povoa; Lieuwe D Bos; Stefano Aliberti; Antoni Torres; Ignacio Martín-Loeches
Journal:  ERJ Open Res       Date:  2017-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.